Boardroom Alpha
Boardroom Alpha
IART · Additional Proxy Materials (DEFA14A) · Filed May 5, 2026

Integra Lifesciences Holdings Corp — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
May 5, 2026
Ticker
IART
Accession
0000917520-26-000038
Boardroom Alpha · Filing insights

Integra LifeSciences: Poul withdraws from director election as Essig becomes CEO; board size reduced.

About Integra Lifesciences Holdings Corp
Market cap
$1.2B
1Y TSR
+14.3%
3Y TSR
−29.2%
Board grade
C-
Sector
Healthcare
CEO
Stuart Essig
Document

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
 
 
Filed by the Registrant 
Filed by a Party other than the Registrant 
Check the appropriate box:

Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) 
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to Section 240.14a-12
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check all boxes that apply):

No fee required
Fee paid previously with preliminary materials 
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 
 



integra-promotionalxlogos_.jpg
Integra LifeSciences Holdings Corporation
1100 Campus Road
Princeton, New Jersey 08540

SUPPLEMENT TO PROXY STATEMENT DATED APRIL 6, 2026
FOR THE ANNUAL MEETING OF STOCKHOLDERS
To Be Held on May 7, 2026

This proxy supplement (the “Supplement”) relates to the Notice of 2026 Annual Meeting of Stockholders and definitive proxy statement of Integra LifeSciences Holdings Corporation (the “Company”), filed with the Securities and Exchange Commission (the “Commission”) on April 6, 2026 (the “Proxy Statement”) in connection with the solicitation of proxies by the Company’s Board of Directors (the “Board”) for use at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) to be held at the Company’s corporate headquarters, 1100 Campus Road, Princeton, New Jersey 08540, on May 7, 2026 at 9:00 a.m. local time.
This Supplement is being filed with the Commission to provide updated information relating to Mojdeh Poul, who was named in the Proxy Statement as a nominee for election as director at the Annual Meeting. Except for the updated information set forth herein, this Supplement does not modify or supplement the Proxy Statement in any manner. This Supplement should be read in conjunction with the Proxy Statement and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 as each contains information that is important to your decisions in voting at the Annual Meeting.
On May 5, 2026, the Company announced that the Board appointed Dr. Stuart M. Essig to serve as President and Chief Executive Officer of the Company, effective as of May 1, 2026. Dr. Essig continues to serve as Chairman of the Board. Ms. Poul ceased to serve as the Company’s President and Chief Executive Officer and as a director of the Board as of the end of the day on April 30, 2026. Accordingly, Ms. Poul will therefore not stand for election as a director of the Company at the Annual Meeting. In connection with Ms. Poul’s departure from the Board, the Board has reduced the number of directors from eight to seven.
Additional Information Regarding Voting
Although Ms. Poul will not stand for election as a director at the Annual Meeting, we will not distribute or issue a new proxy card or voting instruction form to omit Ms. Poul as a nominee for election as a director at the Annual Meeting. The other director nominees named in the Proxy Statement will continue to stand for election as directors at the Annual Meeting. If you have already returned your proxy or provided voting instructions, you do not need to take any action unless you wish to change your vote. Proxies received with instructions to vote for the election of Ms. Poul to the Board will not be voted with respect to her election but will continue to be voted as directed or otherwise as set forth therein and described in the Proxy Statement with respect to all other nominees and matters properly brought before the Annual Meeting. If you have not yet returned your proxy card or submitted your voting instructions, please complete the proxy card or submit instructions disregarding Ms. Poul’s name as a nominee for election to the Board. Information regarding how to vote your shares, or revoke your proxy or voting instructions, is available in the Proxy Statement.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Integra Lifesciences Holdings Corp (IART)

Reference

Frequently asked questions

When did Integra Lifesciences Holdings Corp file this DEFA14A?
Integra Lifesciences Holdings Corp (IART) filed this Additional Proxy Materials (DEFA14A) with the SEC on May 5, 2026. The accession number assigned by EDGAR is 0000917520-26-000038.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Integra LifeSciences: Poul withdraws from director election as Essig becomes CEO; board size reduced. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Integra Lifesciences Holdings Corp's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Integra Lifesciences Holdings Corp has filed under CIK 917520, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer